In March, McKesson finally washed its hands of a decade-old accounting scandal when former CEO Charles McCall was sentenced to 10 years in prison. Maybe that will help people refocus on the company's impressive fundamentals.
With revenues of more than $100 billion, McKesson generates far more top line than its cooler corporate neighbors in Silicon Valley. The company's strong performance during the recession recently prompted Standard & Poor's to upgrade the company's rating.
Best known as the nation's largest distributor of pharmaceuticals -- the company processes some 4.5 million items a day -- McKesson is making inroads on others fronts, digitizing patient records and developing after-hours prescription machines. --P.N.
